C

CEL-SCI Corp
AMEX:CVM

Watchlist Manager
CEL-SCI Corp
AMEX:CVM
Watchlist
Price: 5.27 USD 21.15% Market Closed
Market Cap: 27.1m USD

EV/EBIT
Enterprise Value to EBIT

-1.2
Current
-8.3
Median
5.1
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-1.2
=
Enterprise Value
32m USD
/
EBIT
-26.1m USD
Market Cap EV/EBIT
US
CEL-SCI Corp
AMEX:CVM
27.1m USD -1.2
FR
Pharnext SCA
OTC:PNEXF
6T USD -192 883.8
US
Abbvie Inc
NYSE:ABBV
330.5B USD 22.4
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD -13 207.5
US
Amgen Inc
NASDAQ:AMGN
164.4B USD 24.3
US
Gilead Sciences Inc
NASDAQ:GILD
137.2B USD 13.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.8B USD 27.3
US
Epizyme Inc
F:EPE
94.1B EUR -563.6
AU
CSL Ltd
ASX:CSL
128.5B AUD 23.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.7B USD 13.5
US
Seagen Inc
F:SGT
39.3B EUR -59.9
EBIT Growth EV/EBIT to Growth
US
C
CEL-SCI Corp
AMEX:CVM
Average EV/EBIT: 20.8
Negative Multiple: -1.2
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -192 883.8 N/A N/A
US
Abbvie Inc
NYSE:ABBV
22.4
29%
0.8
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
Negative Multiple: -13 207.5 N/A N/A
US
Amgen Inc
NASDAQ:AMGN
24.3
32%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
13.8
11%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
27.3
17%
1.6
US
E
Epizyme Inc
F:EPE
Negative Multiple: -563.6 N/A N/A
AU
CSL Ltd
ASX:CSL
23.5
14%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.5
11%
1.2
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.9 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-0.8
2-Years Forward
EV/EBIT
-1.1
3-Years Forward
EV/EBIT
-1.9